Unilateral stimulation of the subthalamic nucleus in Parkinson disease: A double-blind 12-month evaluation study

Isabelle M. Germano, Jean Michel Gracies, Donald J. Weisz, Winona Tse, William C. Koller, C. Warren Olanow

Research output: Contribution to journalArticlepeer-review

95 Scopus citations

Abstract

Object. Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) has been established as an effective treatment for Parkinson disease (PD). Nevertheless, bilateral surgical procedures can be associated with frequent and severe complications. The aim in the present study was to assess the safety and efficacy of unilateral STN stimulation, and the need for a second procedure. Methods. Twelve patients with PD underwent unilateral DBS of the STN and were followed up for 12 months. Patients were assessed at baseline and at each visit in a double-blind fashion by analyzing the Unified PD Rating Scale (UPDRS), ambulation speed, and home diaries. Levodopa-off/stimulation-on UPDRS motor scores were improved by 26 ± 8% (p < 0.05, mean ± standard deviation [SD]) compared with the baseline levodopa-off score; there was a 50% improvement in contralateral features, a 17% improvement ipsilaterally, and a 36% improvement in axial features. The mean ambulation speed increased by 83 ± 44% (p < 0.01, mean ± SD). The medication-on time with dyskinesias was significantly reduced (p < 0.01) and the daily levodopa dose was reduced by 19 ± 6% (p < 0.05, mean ± SD). There were no clinically significant side effects. Conclusions. Unilateral DBS of the STN is safe and well tolerated, and may provide sufficient benefit so that additional surgery is not required.

Original languageEnglish
Pages (from-to)36-42
Number of pages7
JournalJournal of Neurosurgery
Volume101
Issue number1
DOIs
StatePublished - Jul 2004

Keywords

  • Deep brain stimulation
  • Parkinson disease
  • Subthalamic nucleus
  • Unilateral stimulation

Fingerprint

Dive into the research topics of 'Unilateral stimulation of the subthalamic nucleus in Parkinson disease: A double-blind 12-month evaluation study'. Together they form a unique fingerprint.

Cite this